parsaclisib + ruxolitinib

Parsaclisib + ruxolitinib is a combination therapy under investigation for the treatment of myelofibrosis, particularly in patients with a suboptimal response to ruxolitinib monotherapy. Parsaclisib is an orally bioavailable, potent, and highly selective next-generation phosphoinositide 3-kinase delta (PI3Kδ) inhibitor. Ruxolitinib is an oral Janus kinase (JAK1/JAK2) inhibitor that reduces spleen volume and improves symptoms in myelofibrosis by blocking dysregulated cell signaling pathways involved in abnormal blood cell proliferation and inflammation. The rationale for combining these agents stems from the observation that some patients have suboptimal responses to JAK inhibition alone due to persistent signaling via the PI3K/protein kinase B pathway. Clinical studies have shown that adding parsaclisib to stable-dose ruxolitinib can further reduce splenomegaly and improve symptom scores with manageable toxicity profiles[1][4][5][8].